Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitro

Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitro

Background: Despite clinical success with anti-spike vaccines, the effectiveness of neutralizing antibodies and vaccines has been compromised by rapidly spreading SARS-CoV-2 variants. Viruses can hijack the glycosylation machinery of host cells to shield themselves from the host's immune respon...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hsiang-Chi Huang, Yun-Ju Lai, Chun-Che Liao, Wang-Feng Yang, Ke-Bin Huang, I-Jung Lee, Wen-Cheng Chou, Shih-Han Wang, Ling-Hui Wang, Jung-Mao Hsu, Cheng-Pu Sun, Chun-Tse Kuo, Jyun Wang, Tzu-Chun Hsiao, Po-Jiun Yang, Te-An Lee, Wilson Huang, Fu-An Li, Chen-Yang Shen, Yi-Ling Lin, Mi-Hua Tao, Chia-Wei Li
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
SARS-CoV-2 variant
STT3A
NGI-1
ADC
Deglycosylation
Medicine
R
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/8fed32a6141e421c81852255ebc22345
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares